Applied Genetic Technologies (AGTC) Reaches $4.39 After 3.00% Up Move; Duke Energy Has …

The stock of Applied Genetic Technologies Corporation (NASDAQ:AGTC) is a huge mover today! The stock increased 8.54% or $0.345 during the last …

Duke Energy Corporation (NYSE:DUK) Logo

The stock of Applied Genetic Technologies Corporation (NASDAQ:AGTC) is a huge mover today! The stock increased 8.54% or $0.345 during the last trading session, reaching $4.385. About 140,646 shares traded or 23.50% up from the average. Applied Genetic Technologies Corporation (NASDAQ:AGTC) has risen 3.54% since March 14, 2018 and is uptrending. It has underperformed by 0.83% the S&P500. Some Historical AGTC News: 10/04/2018 AGTC Announces Completion of Enrollment of Phase 1 / 2 Clinical Study of Investigational Gene Therapy in Patients with X-linked; 08/05/2018 – APPLIED GENETIC TECHNOLOGIES CORP AGTC.O QUARTERLY REVENUE $3.6 MLN VS $31.1 MLN; 20/04/2018 – DJ Applied Genetic Technologies Corp, Inst Holders, 1Q 2018 (AGTC); 30/04/2018 – AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 8, 2018; 30/04/2018 – 4DMT AND ROCHE L-T PACT FOR MULTIPLE AAV GENE THERAPY PRODUCTS; 18/04/2018 – AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa; 30/04/2018 – 4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products; 18/04/2018 – AGTC DOSES FIRST PATIENT IN PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR TREATMENT OF X-LINKED RETINITIS PIGMENTOSA; 08/05/2018 – APPLIED GENETIC TECHNOLOGIES CORP – QTRLY LOSS PER SHARE $0.45; 29/05/2018 – UniQure Gets Patent Covering Methods of Treating Coagulopathies Using AAV Gene Therapy With Nucleic Acid Encoding Hyperactive Factor IX Padua VariantThe move comes after 5 months positive chart setup for the $79.65M company. It was reported on Mar, 14 by Barchart.com. We have $4.52 PT which if reached, will make NASDAQ:AGTC worth $2.39M more.

Duke Energy Corp (DUK) investors sentiment increased to 1.01 in Q4 2018. It’s up 0.10, from 0.91 in 2018Q3. The ratio improved, as 419 investment managers started new or increased equity positions, while 414 decreased and sold their holdings in Duke Energy Corp. The investment managers in our database now own: 437.22 million shares, up from 408.54 million shares in 2018Q3. Also, the number of investment managers holding Duke Energy Corp in top ten equity positions increased from 8 to 11 for an increase of 3. Sold All: 53 Reduced: 361 Increased: 317 New Position: 102.

Analysts await Duke Energy Corporation (NYSE:DUK) to report earnings on May, 9. They expect $1.25 earnings per share, down 2.34% or $0.03 from last year’s $1.28 per share. DUK’s profit will be $908.76M for 18.14 P/E if the $1.25 EPS becomes a reality. After $0.84 actual earnings per share reported by Duke Energy Corporation for the previous quarter, Wall Street now forecasts 48.81% EPS growth.

The stock increased 0.18% or $0.16 during the last trading session, reaching $90.72. About 1.34 million shares traded. Duke Energy Corporation (DUK) has risen 18.95% since March 14, 2018 and is uptrending. It has outperformed by 14.58% the S&P500. Some Historical DUK News: 16/04/2018 – Duke Begins Building Hawaii Solar Farm at Pearl Harbor Navy Base; 29/03/2018 – Duke Energy using North Carolina-based renewable natural gas in first-of-its-kind project; 13/04/2018 – Duke Energy Ohio asks the Ohio Power Siting Board to move forward with its consideration of the Central Corridor Pipeline appli; 26/04/2018 – Grange Insurance Names Damon Porter Chief Human Resources Officer; 11/05/2018 – DUKE CUTS CATAWBA 2 REACTOR TO 65% POWER FROM 100%: NRC; 02/04/2018 – DUKE ENERGY WILL RETIRE CRYSTAL RIVER COAL-FIRED UNITS 1, 2; 27/03/2018 – Charlotte BizJournal: Duke Energy’s revived `Green Source’ renewables program gives advocates the blues; 05/04/2018 – DUKE SAYS BRUNSWICK 1 REACTOR RECONNECTED TO GRID; 22/05/2018 – Duke Energy: Karl Newlin Will Become Senior Vice Pres of Corporate Development; 16/05/2018 – DUKE ENERGY CAROLINAS – WILL BUY ALL OF ENERGY GENERATED BY FACILITIES FOR 5 YEARS THROUGH POWER PURCHASE AGREEMENTS WITH NORTHBROOK ENERGY

More notable recent Duke Energy Corporation (NYSE:DUK) news were published by: Bizjournals.com which released: “Troubled PG&E reportedly close to naming next CEO – San Francisco Business Times” on March 13, 2019, also Seekingalpha.com with their article: “Duke Energy dips into the red as Q4 earnings come up short – Seeking Alpha” published on February 14, 2019, 247Wallst.com published: “Top Analyst Upgrades and Downgrades: Apple, China Mobile, Duke Energy, Facebook, JetBlue, Oracle, Spirit Air, TCR2, Vivint Solar and More – 24/7 Wall St.” on March 11, 2019. More interesting news about Duke Energy Corporation (NYSE:DUK) were released by: Streetinsider.com and their article: “Duke Energy (DUK) Names Marya Rose to Board – StreetInsider.com” published on February 28, 2019 as well as Seekingalpha.com‘s news article titled: “Duke Energy: Wait For A Pullback – Seeking Alpha” with publication date: February 05, 2019.

Duke Energy Corporation, together with its subsidiaries, operates as an energy firm in the United States. The company has market cap of $65.95 billion. It operates through three divisions: Electric Utilities and Infrastructure, Gas Utilities and Infrastructure, and Commercial Renewables. It has a 24.15 P/E ratio. The Electric Utilities and Infrastructure segment generates, transmits, distributes, and sells electricity in the Carolinas, Florida, and the Midwest; uses coal, hydroelectric, natural gas, oil, renewable generation, and nuclear fuel to generate electricity; and engages in the wholesale of electricity to municipalities, electric cooperative utilities, and other load-serving entities.

Bruce & Co. Inc. holds 6.39% of its portfolio in Duke Energy Corporation for 347,788 shares. Cincinnati Casualty Co owns 66,300 shares or 5.31% of their US portfolio. Moreover, Canal Insurance Co has 4.8% invested in the company for 150,166 shares. The Pennsylvania-based Symons Capital Management Inc has invested 4.8% in the stock. Stralem & Co Inc, a New York-based fund reported 71,345 shares.

More notable recent Applied Genetic Technologies Corporation (NASDAQ:AGTC) news were published by: Nasdaq.com which released: “Investors Real Estate Trust (IRET) Ex-Dividend Date Scheduled for March 14, 2019 – Nasdaq” on March 13, 2019, also Benzinga.com with their article: “Wells Fargo Bullish On Applied Genetic Technologies (NASDAQ:AGTC) Ahead Of Program Update – Benzinga” published on September 24, 2018, Seekingalpha.com published: “Applied Genetic Tech’s gene therapy fails to show effect in XLRS study; Biogen collaboration terminated – Seeking Alpha” on December 12, 2018. More interesting news about Applied Genetic Technologies Corporation (NASDAQ:AGTC) were released by: Nasdaq.com and their article: “AGTC Slumps After-hrs, NBIX Fails To Strike GOLD, IDRA To Report Data On Dec.14 – Nasdaq” published on December 13, 2018 as well as Benzinga.com‘s news article titled: “Sell-Side Roundup: What’s Next For For Applied Genetic (NASDAQ:AGTC) After 50% Plunge? – Benzinga” with publication date: December 13, 2018.

Investors sentiment decreased to 0.61 in Q4 2018. Its down 0.43, from 1.04 in 2018Q3. It dropped, as 11 investors sold Applied Genetic Technologies Corporation shares while 17 reduced holdings. 10 funds opened positions while 7 raised stakes. 6.24 million shares or 1.41% less from 6.33 million shares in 2018Q3 were reported. Cubist Systematic Strategies Limited Liability, Connecticut-based fund reported 1,115 shares. The United Kingdom-based Barclays Public Limited Company has invested 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Bridgeway Management stated it has 126,700 shares. Dafna Capital Management Ltd invested 0.44% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Northern accumulated 20,573 shares. Connor Clark Lunn Ltd accumulated 52,925 shares or 0% of the stock. Ameriprise Fincl reported 10,128 shares stake. 499 were accumulated by Bnp Paribas Arbitrage. The New York-based Savings Bank Of New York Mellon has invested 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Acadian Asset Mgmt Ltd Company owns 0.01% invested in Applied Genetic Technologies Corporation (NASDAQ:AGTC) for 674,754 shares. Morgan Stanley holds 36,287 shares or 0% of its portfolio. 82,686 are owned by Geode Cap Mgmt Limited Liability. Meeder Asset Management holds 397 shares or 0% of its portfolio. Renaissance Techs Limited Com invested in 848,100 shares. Vanguard Gru stated it has 556,836 shares.

Analysts await Applied Genetic Technologies Corporation (NASDAQ:AGTC) to report earnings on May, 14. They expect $-0.54 earnings per share, down 20.00% or $0.09 from last year’s $-0.45 per share. After $-0.23 actual earnings per share reported by Applied Genetic Technologies Corporation for the previous quarter, Wall Street now forecasts 134.78% negative EPS growth.

Among 2 analysts covering Applied Genetic Tech (NASDAQ:AGTC), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Applied Genetic Tech had 2 analyst reports since September 24, 2018 according to SRatingsIntel. The firm has “Outperform” rating given on Monday, September 24 by Wells Fargo. The firm has “Market Perform” rating given on Thursday, December 13 by BMO Capital Markets.

Duke Energy Corporation (NYSE:DUK) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Biogen Inc (NASDAQ:BIIB) Shares Sold by Castleark Management LLC

AQR Capital Management LLC increased its position in Biogen by 6.5% during the third quarter. AQR Capital Management LLC now owns 3,024,037 …

Biogen logoCastleark Management LLC lessened its position in Biogen Inc (NASDAQ:BIIB) by 45.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,759 shares of the biotechnology company’s stock after selling 17,306 shares during the period. Castleark Management LLC’s holdings in Biogen were worth $6,247,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. BlackRock Inc. increased its position in Biogen by 0.4% during the fourth quarter. BlackRock Inc. now owns 16,568,963 shares of the biotechnology company’s stock worth $4,985,931,000 after purchasing an additional 70,603 shares during the last quarter. Oregon Public Employees Retirement Fund increased its position in Biogen by 27,620.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 14,309,047 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 14,257,427 shares during the last quarter. AQR Capital Management LLC increased its position in Biogen by 6.5% during the third quarter. AQR Capital Management LLC now owns 3,024,037 shares of the biotechnology company’s stock worth $1,068,422,000 after purchasing an additional 183,542 shares during the last quarter. Capital World Investors increased its position in Biogen by 503.2% during the third quarter. Capital World Investors now owns 2,473,708 shares of the biotechnology company’s stock worth $873,986,000 after purchasing an additional 2,063,598 shares during the last quarter. Finally, Jackson Square Partners LLC grew its stake in Biogen by 5.7% during the third quarter. Jackson Square Partners LLC now owns 2,241,778 shares of the biotechnology company’s stock worth $792,042,000 after buying an additional 121,072 shares during the period. 88.94% of the stock is owned by institutional investors and hedge funds.

BIIB has been the subject of several research reports. BMO Capital Markets assumed coverage on shares of Biogen in a research note on Friday, February 22nd. They set a “market perform” rating and a $322.00 price objective for the company. Mizuho set a $427.00 target price on shares of Biogen and gave the company a “buy” rating in a research note on Tuesday, January 29th. Oppenheimer decreased their target price on shares of Biogen from $380.00 to $372.00 and set an “outperform” rating for the company in a research note on Tuesday, December 18th. Royal Bank of Canada cut their price target on shares of Biogen to $338.00 and set a “sector perform” rating on the stock in a report on Monday, November 26th. Finally, ValuEngine cut shares of Biogen from a “hold” rating to a “sell” rating in a report on Wednesday, December 19th. Ten analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $370.28.

Shares of BIIB stock traded up $6.55 during trading hours on Wednesday, reaching $319.27. The stock had a trading volume of 17,327 shares, compared to its average volume of 1,233,484. The company has a quick ratio of 2.04, a current ratio of 2.32 and a debt-to-equity ratio of 0.46. Biogen Inc has a twelve month low of $249.17 and a twelve month high of $388.67. The stock has a market cap of $61.45 billion, a PE ratio of 12.17, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, January 29th. The biotechnology company reported $6.99 earnings per share for the quarter, topping the Zacks’ consensus estimate of $6.72 by $0.27. Biogen had a net margin of 32.94% and a return on equity of 40.53%. The business had revenue of $3.53 billion for the quarter, compared to analysts’ expectations of $3.39 billion. During the same quarter last year, the company earned $5.26 EPS. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. Equities analysts forecast that Biogen Inc will post 28.68 EPS for the current fiscal year.

In related news, Director Alexander J. Denner purchased 7,000 shares of Biogen stock in a transaction dated Friday, February 1st. The stock was acquired at an average cost of $328.45 per share, with a total value of $2,299,150.00. Following the completion of the transaction, the director now directly owns 10,909 shares of the company’s stock, valued at $3,583,061.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alexander J. Denner purchased 30,000 shares of Biogen stock in a transaction dated Wednesday, January 30th. The stock was bought at an average cost of $324.86 per share, with a total value of $9,745,800.00. Following the completion of the transaction, the director now directly owns 10,909 shares of the company’s stock, valued at $3,543,897.74. The disclosure for this purchase can be found here. Company insiders own 0.29% of the company’s stock.

WARNING: “Biogen Inc (NASDAQ:BIIB) Shares Sold by Castleark Management LLC” was first reported by Fairfield Current and is the property of of Fairfield Current. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.fairfieldcurrent.com/news/2019/03/13/biogen-inc-biib-shares-sold-by-castleark-management-llc.html.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.

Recommended Story: Net Margin

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biogen and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Biogen Inc (NASDAQ:BIIB) Shares Sold by Meiji Yasuda Asset Management Co Ltd.

AQR Capital Management LLC grew its holdings in shares of Biogen by 6.5% during the third quarter. AQR Capital Management LLC now owns …

Biogen logoMeiji Yasuda Asset Management Co Ltd. decreased its stake in Biogen Inc (NASDAQ:BIIB) by 6.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,866 shares of the biotechnology company’s stock after selling 452 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in Biogen were worth $2,066,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Biogen by 0.4% in the fourth quarter. BlackRock Inc. now owns 16,568,963 shares of the biotechnology company’s stock worth $4,985,931,000 after acquiring an additional 70,603 shares in the last quarter. Oregon Public Employees Retirement Fund grew its holdings in shares of Biogen by 27,620.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 14,309,047 shares of the biotechnology company’s stock worth $48,000 after buying an additional 14,257,427 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Biogen by 6.5% during the third quarter. AQR Capital Management LLC now owns 3,024,037 shares of the biotechnology company’s stock worth $1,068,422,000 after buying an additional 183,542 shares in the last quarter. Capital World Investors grew its holdings in shares of Biogen by 503.2% during the third quarter. Capital World Investors now owns 2,473,708 shares of the biotechnology company’s stock worth $873,986,000 after buying an additional 2,063,598 shares in the last quarter. Finally, Jackson Square Partners LLC grew its holdings in shares of Biogen by 5.7% during the third quarter. Jackson Square Partners LLC now owns 2,241,778 shares of the biotechnology company’s stock worth $792,042,000 after buying an additional 121,072 shares in the last quarter. 88.94% of the stock is currently owned by institutional investors and hedge funds.

BIIB has been the subject of a number of research reports. Oppenheimer set a $372.00 price objective on Biogen and gave the stock a “buy” rating in a report on Friday, January 25th. Morgan Stanley increased their price objective on Biogen from $394.00 to $401.00 and gave the stock an “overweight” rating in a report on Wednesday, December 19th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Biogen in a research report on Thursday, January 10th. Citigroup increased their price target on Biogen from $372.00 to $380.00 and gave the company an “outperform” rating in a research report on Wednesday, January 30th. Finally, ValuEngine raised Biogen from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Ten research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Biogen currently has an average rating of “Buy” and a consensus target price of $370.28.

Shares of BIIB traded down $7.36 during midday trading on Friday, hitting $307.93. The company’s stock had a trading volume of 1,601,073 shares, compared to its average volume of 1,225,704. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.04 and a current ratio of 2.32. Biogen Inc has a one year low of $249.17 and a one year high of $388.67. The firm has a market cap of $60.57 billion, a price-to-earnings ratio of 11.75, a PEG ratio of 1.15 and a beta of 1.13.

Biogen (NASDAQ:BIIB) last issued its earnings results on Tuesday, January 29th. The biotechnology company reported $6.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.72 by $0.27. Biogen had a return on equity of 40.53% and a net margin of 32.94%. The business had revenue of $3.53 billion during the quarter, compared to analysts’ expectations of $3.39 billion. During the same quarter in the prior year, the firm earned $5.26 EPS. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, research analysts forecast that Biogen Inc will post 28.68 EPS for the current fiscal year.

In related news, Director Alexander J. Denner bought 30,000 shares of the business’s stock in a transaction on Wednesday, January 30th. The shares were purchased at an average cost of $324.86 per share, with a total value of $9,745,800.00. Following the acquisition, the director now owns 10,909 shares of the company’s stock, valued at $3,543,897.74. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Alexander J. Denner bought 7,000 shares of the business’s stock in a transaction on Friday, February 1st. The shares were bought at an average cost of $328.45 per share, for a total transaction of $2,299,150.00. Following the completion of the acquisition, the director now directly owns 10,909 shares in the company, valued at approximately $3,583,061.05. The disclosure for this purchase can be found here. 0.29% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/03/10/meiji-yasuda-asset-management-co-ltd-has-2-07-million-position-in-biogen-inc-biib.html.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.

Further Reading: What is the float in trading stocks?

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biogen and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Samlyn Capital Lowered Its Biogen (BIIB) Stake by $16.68 Million; Shares Declined; Qualcomm …

… of the Holding of the Annual Meeting; 11/04/2018 – Brain Corp CEO Dr. Eugene lzhikevich to Speak at CONNECT; 14/05/2018 – Gulf News: Trump, …

Biogen Inc. (NASDAQ:BIIB) Logo

Mathes Company Inc increased its stake in Qualcomm Inc. (QCOM) by 190% based on its latest 2018Q4 regulatory filing with the SEC. Mathes Company Inc bought 5,700 shares as the company’s stock declined 5.07% while stock markets rallied. The institutional investor held 8,700 shares of the radio and television broadcasting and communications equipment company at the end of 2018Q4, valued at $495,000, up from 3,000 at the end of the previous reported quarter. Mathes Company Inc who had been investing in Qualcomm Inc. for a number of months, seems to be bullish on the $64.76B market cap company. The stock decreased 0.96% or $0.52 during the last trading session, reaching $53.51. About 2.71 million shares traded. QUALCOMM Incorporated (NASDAQ:QCOM) has declined 17.21% since March 8, 2018 and is downtrending. It has underperformed by 21.58% the S&P500. Some Historical QCOM News: 19/03/2018 – FierceWireEurope: Qualcomm: It’s not over; 16/03/2018 – Qualcomm: Board Will Consist of 10 Directors Effective as of the Holding of the Annual Meeting; 11/04/2018 – Brain Corp CEO Dr. Eugene lzhikevich to Speak at CONNECT; 14/05/2018 – Gulf News: Trump, Xi ease trade tensions with ZTE, Qualcomm reversals; 05/03/2018 – QUALCOMM – BROADCOM HAS BEEN INTERACTING WITH CFIUS “FOR WEEKS” AND MADE TWO WRITTEN SUBMISSIONS TO CFIUS; 07/05/2018 – VentureBeat: Microsoft open-sources Azure IoT Edge runtime, embraces more Kubernetes, partners with DJI and Qualcomm #Build2018; 15/03/2018 – REFILE-UPDATE 3-With Qualcomm behind it, Broadcom looks to smaller deals; 08/03/2018 – blacq: Exclusive: Secretive U.S. security panel discussing Broadcom’s Qualcomm bid – sources WASHINGTON (Reuters); 09/03/2018 – Qualcomm: Focused on Maximizing Holder Value; Will Consider All Options to Achieve That Objective; 16/03/2018 – JACOBS SEES CLEAR MERITS TO EXPLORING PATH TO TAKE QCOM PRIVATE

Samlyn Capital Llc decreased its stake in Biogen Inc (BIIB) by 30.18% based on its latest 2018Q4 regulatory filing with the SEC. Samlyn Capital Llc sold 55,606 shares as the company’s stock declined 1.50% while stock markets rallied. The hedge fund held 128,645 shares of the biological products (no diagnostic substances) company at the end of 2018Q4, valued at $38.71 million, down from 184,251 at the end of the previous reported quarter. Samlyn Capital Llc who had been investing in Biogen Inc for a number of months, seems to be less bullish one the $60.89 billion market cap company. The stock decreased 1.82% or $5.75 during the last trading session, reaching $309.54. About 255,437 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 15.91% since March 8, 2018 and is uptrending. It has outperformed by 11.54% the S&P500. Some Historical BIIB News: 17/05/2018 – FDA’S GOTTLIEB – COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE BIOGEN IDEC, INSYS THERAPEUTICS, LUNDBECK LLC, HYPERION THERAPEUTICS, VIVUS INC; 12/03/2018 – Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia; 20/04/2018 – BIOGEN INC – IN COLLABORATION, IONIS WILL BE RESPONSIBLE FOR IDENTIFICATION OF ANTISENSE DRUG CANDIDATES BASED ON SELECTED TARGETS; 05/04/2018 – Samsung, Biogen Reach Deal With AbbVie to Sell Near Copy of Humira; 05/03/2018 VP McKenzie Disposes 110 Of Biogen Inc; 07/03/2018 – EMA- EMA RECOMMENDATION FOLLOWING 12 REPORTS OF SERIOUS INFLAMMATORY BRAIN DISORDERS WORLDWIDE, INCLUDING ENCEPHALITIS AND MENINGOENCEPHALITIS; 15/05/2018 – Bridgewater Adds Biogen, Exits Costco, Buys More Newfield: 13F; 24/04/2018 – Biogen Idec 1Q Net $1.2B; 20/04/2018 – FDA: Biologic License Application (BLA): 125104 Company: BIOGEN IDEC; 05/04/2018 – BIOGEN INC – UNDER TERMS OF AGREEMENT, BIOGEN AND SAMSUNG BIOEPIS WILL MAKE ROYALTY PAYMENTS TO ABBVIE

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on April, 23. They expect $6.90 EPS, up 14.05% or $0.85 from last year’s $6.05 per share. BIIB’s profit will be $1.36B for 11.22 P/E if the $6.90 EPS becomes a reality. After $6.99 actual EPS reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -1.29% negative EPS growth.

Investors sentiment decreased to 0.91 in Q4 2018. Its down 0.10, from 1.01 in 2018Q3. It dropped, as 79 investors sold BIIB shares while 314 reduced holdings. 83 funds opened positions while 276 raised stakes. 181.17 million shares or 8.34% more from 167.21 million shares in 2018Q3 were reported. Gradient Investments Ltd Liability Com has invested 0% in Biogen Inc. (NASDAQ:BIIB). 219,754 are held by Hsbc Hldgs Public Limited Company. Gam Holdg Ag owns 13,477 shares. Athena Capital Limited Liability Corp holds 0.04% in Biogen Inc. (NASDAQ:BIIB) or 410 shares. Gateway Invest Advisers Limited Liability Com reported 128,214 shares stake. Next Financial Group Incorporated reported 389 shares stake. 1,534 are owned by Alta Mngmt Limited Liability Company. Rhenman Partners Asset Management Ab invested in 2.06% or 60,000 shares. Raymond James Advisors Inc holds 26,643 shares or 0.04% of its portfolio. Moreover, Old National Financial Bank In has 0.22% invested in Biogen Inc. (NASDAQ:BIIB). Roberts Glore & Il accumulated 2,589 shares. The Michigan-based Comerica Bankshares has invested 0.12% in Biogen Inc. (NASDAQ:BIIB). Systematic Limited Partnership holds 5,600 shares or 0.05% of its portfolio. Amer Assets Investment Management Lc reported 8,000 shares stake. West Oak Capital Ltd Limited Liability Company stated it has 4,802 shares or 0% of all its holdings.

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Nasdaq.com which released: “NITE, BIIB: Nightstar Therapeutics Stock Soars on Biogen Buy – Nasdaq” on March 04, 2019, also Nasdaq.com with their article: “Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More – Nasdaq” published on March 06, 2019, Seekingalpha.com published: “Biogen down 3% after hours on Mylan patent challenge – Seeking Alpha” on February 06, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Nasdaq.com and their article: “Mid-Morning Market Update: Markets Open Higher; Childrens Place Misses Q4 Expectations – Nasdaq” published on March 04, 2019 as well as Seekingalpha.com‘s news article titled: “Time To Add Downside Protection To Biogen? – Seeking Alpha” with publication date: February 06, 2019.

Samlyn Capital Llc, which manages about $7.24 billion and $4.21B US Long portfolio, upped its stake in Athene Hldg Ltd by 946,829 shares to 3.90 million shares, valued at $155.14 million in 2018Q4, according to the filing. It also increased its holding in Walmart Inc (NYSE:WMT) by 107,995 shares in the quarter, for a total of 214,622 shares, and has risen its stake in Kohls Corp (NYSE:KSS).

Since September 26, 2018, it had 1 buy, and 1 sale for $20.22 million activity. 1,000 shares were sold by Ehlers Michael D, worth $350,000.

Mathes Company Inc, which manages about $240.09M and $158.52 million US Long portfolio, decreased its stake in John Bean Technologies Corp. (NYSE:JBT) by 6,080 shares to 28,555 shares, valued at $2.05 million in 2018Q4, according to the filing. It also reduced its holding in Union Pacific Corp (NYSE:UNP) by 4,943 shares in the quarter, leaving it with 20,422 shares, and cut its stake in Salesforce.Com Inc (NYSE:CRM).

Since September 27, 2018, it had 0 insider buys, and 8 sales for $12.25 million activity. 40,000 shares valued at $2.03 million were sold by THOMPSON JAMES H on Monday, February 11. Rosenberg Donald J sold $347,746 worth of stock. 853 QUALCOMM Incorporated (NASDAQ:QCOM) shares with value of $54,166 were sold by ROGERS ALEXANDER H.

Investors sentiment decreased to 0.73 in 2018 Q4. Its down 0.04, from 0.77 in 2018Q3. It is negative, as 91 investors sold QCOM shares while 491 reduced holdings. 104 funds opened positions while 322 raised stakes. 1.00 billion shares or 4.55% less from 1.05 billion shares in 2018Q3 were reported. Private Advisor Ltd Co holds 0.06% or 46,141 shares in its portfolio. Employees Retirement System Of Texas holds 266,886 shares or 0.24% of its portfolio. Park Circle Com has invested 0.04% in QUALCOMM Incorporated (NASDAQ:QCOM). Klingenstein Fields & Limited Liability Company holds 6,157 shares or 0.01% of its portfolio. Causeway Cap Management Ltd Liability Corp reported 2.13% of its portfolio in QUALCOMM Incorporated (NASDAQ:QCOM). Proshare Advsr Llc has 0.39% invested in QUALCOMM Incorporated (NASDAQ:QCOM) for 986,769 shares. Td Management Ltd Liability owns 101 shares for 0% of their portfolio. The Ohio-based Cleararc Capital has invested 0.35% in QUALCOMM Incorporated (NASDAQ:QCOM). Loring Wolcott Coolidge Fiduciary Limited Liability Partnership Ma owns 210,264 shares for 0.22% of their portfolio. Walter And Keenan Fincl Consulting Communications Mi Adv invested 0.62% of its portfolio in QUALCOMM Incorporated (NASDAQ:QCOM). 212,021 were accumulated by Thompson Siegel And Walmsley Lc. Brown Advisory owns 178,927 shares or 0.03% of their US portfolio. Usca Ria Limited Liability Co reported 160,451 shares or 1.21% of all its holdings. The New York-based Kimelman Baird Ltd Liability Company has invested 0.09% in QUALCOMM Incorporated (NASDAQ:QCOM). Spirit Of America Mgmt Corp accumulated 7,200 shares.

QUALCOMM Incorporated (NASDAQ:QCOM) Institutional Positions Chart

Related Posts:

  • No Related Posts

Cullen Capital Management Boosted Position in Intel Corp. (INTC) as Valuation Rose; Bb&T Has …

… 08/05/2018 – Movellus Closes Funding From Intel Capital for Digital Tool Expansion Technology; 27/03/2018 – Xplore Wins Best PC Client Platform …

Biogen Inc. (NASDAQ:BIIB) Logo

Bb&T Corp increased its stake in Biogen Inc (BIIB) by 988.16% based on its latest 2018Q4 regulatory filing with the SEC. Bb&T Corp bought 19,615 shares as the company’s stock declined 1.50% while stock markets rallied. The institutional investor held 21,600 shares of the biological products (no diagnostic substances) company at the end of 2018Q4, valued at $6.50 million, up from 1,985 at the end of the previous reported quarter. Bb&T Corp who had been investing in Biogen Inc for a number of months, seems to be bullish on the $62.09 billion market cap company. The stock decreased 0.73% or $2.32 during the last trading session, reaching $315.65. About 587,894 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 15.91% since March 7, 2018 and is uptrending. It has outperformed by 11.54% the S&P500. Some Historical BIIB News: 13/04/2018 – Brightwire: Biogen likely to exercise option to raise stake in Samsung Bioepis, insiders say; 05/04/2018 – BIOGEN & SAMSUNG BIOEPIS AGREE TO SETTLEMENT WITH ABBVIE; 01/05/2018 – BIIB TO MAKE 1-TIME $50M PAYMENT TO NEURIMMUNE FOR 5% REDUCTION; 20/04/2018 – BIOGEN WILL PAY IONIS $1B IN CASH; 25/05/2018 – Biogen’s Avonex Sales Rise; Multiple Sclerosis Market Up 1%; 01/05/2018 – BIOGEN, NEURIMMUNE OPTION EXERCISE FOR ALZHEIMER’S TREATMENT; 24/04/2018 – BIOGEN 1Q REV. $3.1B, EST. $3.15B; 17/05/2018 – FDA’S GOTTLIEB – COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE BIOGEN IDEC, INSYS THERAPEUTICS, LUNDBECK LLC, HYPERION THERAPEUTICS, VIVUS INC; 24/04/2018 – Biotech Drug Production Pipeline Increasing Amid Buzz of Market Optimism; 12/03/2018 – Biogen To Buy Schizophrenia Treatment From Pfizer For Up To $590 Million — MarketWatch

Cullen Capital Management Llc increased its stake in Intel Corp. (INTC) by 0.91% based on its latest 2018Q4 regulatory filing with the SEC. Cullen Capital Management Llc bought 7,575 shares as the company’s stock rose 10.40% with the market. The institutional investor held 838,550 shares of the semiconductors company at the end of 2018Q4, valued at $39.35 million, up from 830,975 at the end of the previous reported quarter. Cullen Capital Management Llc who had been investing in Intel Corp. for a number of months, seems to be bullish on the $236.07 billion market cap company. The stock decreased 0.86% or $0.46 during the last trading session, reaching $52.49. About 12.35M shares traded. Intel Corporation (NASDAQ:INTC) has risen 12.75% since March 7, 2018 and is uptrending. It has outperformed by 8.38% the S&P500. Some Historical INTC News: 02/04/2018 – APPLE IS PLANNING TO MOVE FROM INTEL CHIPS TO ITS OWN MAC CHIPS – CNBC, CITING REPORT; 20/04/2018 – House Intel Dems: Intel Ranking Member Schiff Statement on Comey Memos; 16/04/2018 – Tech Report: Rumor: Intel partner docs add to eight-core Coffee Lake CPU chatter; 12/03/2018 – Australian Gov: WIPO PUBLISHES PATENT OF INTEL FOR “MAINTAINING A SOURCE ENB CONNECTION DURING HANDOVER” (CHINESE, AMERICAN; 26/04/2018 – INTEL CORP – CO EXPECTS FULL YEAR TAX RATE OF 13 PERCENT, ONE POINT LOWER THAN PRIOR ESTIAMTE – CFO, CONF CALL; 22/05/2018 – Intel Finds Another Chip Exploit, Says Fix Is in Place (Correct); 04/04/2018 – GigaSpaces InsightEdge Platform with Intel® Technology Accelerates AI Innovations; 26/04/2018 – INTEL CORP – KELLER JOINS INTEL FROM TESLA; 08/05/2018 – Movellus Closes Funding From Intel Capital for Digital Tool Expansion Technology; 27/03/2018 – Xplore Wins Best PC Client Platform at Intel Technology Partner Awards

Since October 25, 2018, it had 2 buys, and 9 sales for $893,356 activity. $245,993 worth of stock was bought by SWAN ROBERT HOLMES on Thursday, December 6. $102,050 worth of stock was sold by Rodgers Steven Ralph on Thursday, October 25. McBride Kevin Thomas also sold $295,945 worth of Intel Corporation (NASDAQ:INTC) on Tuesday, October 30.

More notable recent Intel Corporation (NASDAQ:INTC) news were published by: Seekingalpha.com which released: “Intel -1.4% on new security issue report – Seeking Alpha” on March 05, 2019, also Nasdaq.com with their article: “After Hours Most Active for Mar 1, 2019 : ABEV, GE, XOM, PFE, AR, TSM, SGMS, AAPL, SHY, MSFT, MCHI, INTC – Nasdaq” published on March 01, 2019, Marketwatch.com published: “If you own Apple, Amazon, Facebook or AMD, look out below – MarketWatch” on February 07, 2019. More interesting news about Intel Corporation (NASDAQ:INTC) were released by: Nasdaq.com and their article: “Intel (INTC) Ups the Ante in Hardware Security With SGX Card – Nasdaq” published on February 28, 2019 as well as Nasdaq.com‘s news article titled: “3 Big Stock Charts for Thursday: Conagra Brands, Intel and Franklin Resources – Nasdaq” with publication date: February 14, 2019.

Investors sentiment increased to 1 in 2018 Q4. Its up 0.15, from 0.85 in 2018Q3. It is positive, as 52 investors sold INTC shares while 677 reduced holdings. 141 funds opened positions while 588 raised stakes. 2.96 billion shares or 3.57% more from 2.86 billion shares in 2018Q3 were reported. Warren Averett Asset Mngmt Limited Com, a Alabama-based fund reported 10,874 shares. Plancorp Limited Liability Company invested in 6,265 shares. Alpha Cubed Limited stated it has 415,943 shares or 2.92% of all its holdings. Lincoln Cap Ltd owns 5,845 shares. Cullen Frost Bankers Inc has 0.34% invested in Intel Corporation (NASDAQ:INTC) for 196,031 shares. Community Grp Inc Ltd reported 1.11% of its portfolio in Intel Corporation (NASDAQ:INTC). Private Wealth Advsr reported 57,626 shares stake. Of Vermont reported 1% in Intel Corporation (NASDAQ:INTC). Provise Grp Inc Ltd Llc reported 19,704 shares or 0.15% of all its holdings. Lingohr & Partner Asset Mgmt Gmbh holds 0.88% in Intel Corporation (NASDAQ:INTC) or 17,476 shares. Raymond James And Associate has 3.69M shares. West Oak Ltd Liability Corporation reported 47,471 shares. Comerica Bancorporation holds 0.74% in Intel Corporation (NASDAQ:INTC) or 1.87M shares. Cap Rech Global Investors owns 97.61 million shares. Aldebaran reported 8,304 shares.

Cullen Capital Management Llc, which manages about $3.87 billion and $2.32B US Long portfolio, decreased its stake in Vale Sa (Adr) (NYSE:VALE) by 288,350 shares to 791,450 shares, valued at $10.44 million in 2018Q4, according to the filing. It also reduced its holding in Allianz Se by 3,600 shares in the quarter, leaving it with 25,855 shares, and cut its stake in Royal Dutch Shell Class B (RYDBF).

Since September 26, 2018, it had 1 buy, and 1 insider sale for $20.22 million activity. DENNER ALEXANDER J also bought $20.57M worth of Biogen Inc. (NASDAQ:BIIB) on Wednesday, January 30.

Investors sentiment decreased to 0.91 in 2018 Q4. Its down 0.10, from 1.01 in 2018Q3. It turned negative, as 79 investors sold BIIB shares while 314 reduced holdings. 83 funds opened positions while 276 raised stakes. 181.17 million shares or 8.34% more from 167.21 million shares in 2018Q3 were reported. Moreover, Aperio Group Ltd has 0.24% invested in Biogen Inc. (NASDAQ:BIIB) for 160,705 shares. Ferguson Wellman Cap Management invested 0.04% in Biogen Inc. (NASDAQ:BIIB). Rathbone Brothers Public Ltd Co reported 0.04% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Everence Cap Mngmt reported 0.33% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Wolverine Asset Limited Liability Corp reported 0% in Biogen Inc. (NASDAQ:BIIB). Louisiana State Employees Retirement System accumulated 10,600 shares or 0.18% of the stock. State Street holds 0.24% in Biogen Inc. (NASDAQ:BIIB) or 8.78 million shares. 3,074 are held by Walleye Trading Limited Liability Co. 4,231 are owned by Bremer Tru Natl Association. Highvista Strategies Ltd Company invested in 7.47% or 28,709 shares. Midas Mngmt Corporation reported 1,400 shares. Prudential Public Limited Co invested 0.14% in Biogen Inc. (NASDAQ:BIIB). Amica Pension Fund Board Of Trustees owns 6,442 shares or 0.3% of their US portfolio. Community Serv Group has 0.08% invested in Biogen Inc. (NASDAQ:BIIB). Mairs And Incorporated invested 0% of its portfolio in Biogen Inc. (NASDAQ:BIIB).

Bb&T Corp, which manages about $4.88B US Long portfolio, decreased its stake in Ford Motor Compa (NYSE:F) by 52,045 shares to 86,354 shares, valued at $661,000 in 2018Q4, according to the filing. It also reduced its holding in Dowdupont Inc by 13,641 shares in the quarter, leaving it with 127,935 shares, and cut its stake in Lam Research Cor (NASDAQ:LRCX).

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Seekingalpha.com which released: “Biogen’s Spinraza OK’d in China – Seeking Alpha” on February 28, 2019, also Seekingalpha.com with their article: “Biogen 2019 Outlook – Seeking Alpha” published on February 11, 2019, Nasdaq.com published: “Surprising Analyst 12-Month Target For OEW – Nasdaq” on February 25, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Fool.com and their article: “Here’s Why Ionis Pharmaceuticals Jumped Higher Today – Motley Fool” published on February 27, 2019 as well as Nasdaq.com‘s news article titled: “Notable ETF Outflow Detected – IBB, BIIB, ILMN, REGN – Nasdaq” with publication date: February 14, 2019.

Intel Corporation (NASDAQ:INTC) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts